(lp0
S"Celldex Therapeutics, Inc. Is Feeling Some Pressure Today -- Here's Why Motley Fool - Mar 7, 2017 Shares of Celldex Therapeutics, Inc.  a clinical-stage biotech developing targeted cancer therapies, were down about 10% as of 2:45 p.m.Celldex Therapeutics  Q4 Earnings: What's in Store? - Yahoo FinanceIs Celldex Therapeutics  The Next TG Therapeutics Inc   "
p1
aS'Celldex Therapeutics, Inc. Ends Q4 With Plenty of Cash and Several Key Studies ... Motley Fool - Mar 14, 2017 Celldex Therapeutics CEO Anthony Marucci focused on where his company is headed: &quot;Celldex made important progress across our pipeline in the fourth quarter, including successfully completing the integration of Kolltan Pharmaceuticals and its novel RTK&nbsp;...Celldex Provides Corporate Update and Reports Full Year 2016 Results - GlobeNewswire Analyst Activity  Jefferies Group LLC Lowers Its Price Target On Celldex ... - Market Exclusive'
p2
aS'Why You Should  Buy Celldex Therapeutics, Inc. Motley Fool - Dec 6, 2016 Despite a bustling development schedule, the company burned through just $96 million in the first nine months of the year. If glemba succeeds, Celldex Therapeutics might be able to launch its first drug without heavily diluting shareholder value. If it ...'
p3
aS"Better Buy: Celldex Therapeutics, Inc. vs. Juno Therapeutics Inc Motley Fool - Feb 28, 2017 Celldex Therapeutics, Inc.  and Juno Therapeutics Inc  are two of last year's worst-performing biotech stocks.Celldex Therapeutics, Inc.  Closed the Last Trading Session at $3.56 - The Newburgh PressShares of Celldex Therapeutics, Inc.  Plunge -6.59% - Energy Index"
p4
aS"Just the Facts on Celldex Therapeutics, Inc.  StockNewsJournal - 15 hours ago Celldex Therapeutics, Inc.  is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $3.28, up from yesterday's close by 0.61%.Celldex Therapeutics, Inc.  Stock with Perks - The Newburgh PressCelldex Therapeutics, Inc.  Receives $7.63 Consensus Target Price from ... - BBNS"
p5
aS"Analyst Research Roundup: Celldex Therapeutics, Inc.  StandardOracle - Apr 12, 2017 Celldex Therapeutics, Inc.  lost -0.3% to reach $3.29 in the previous trading session. Overall, 1.33 Million shares exchanged hands versus its average trading volume of 1.94 Million shares.Celldex Therapeutics, Inc.  Earns Buy Rating from Aegis - The Cerbat GemToday's Analyst Moves: Celldex Therapeutics, Inc. , Citrix Systems, Inc ... - USA Commerce Daily"
p6
aS"Today's Research Reports on Stocks to Watch: Celldex Therapeutics and PDL ... Yahoo Finance - Mar 31, 2017 NEW YORK, NY / ACCESSWIRE / March 31, 2017 / Celldex Therapeutics' stock might be plummeting but Wall Street still remains adamant that the company's stock could rise significantly in value. The company's kiln still has metal heating up, with clinical&nbsp;..."
p7
aS'Experts proposition on the searing stocks: Celldex Therapeutics, Inc. (CLDX ... The USA Commerce - 22 hours ago On the close of 04/13/2017 Celldex Therapeutics, Inc.  jumped 0.61% to hit $3.28. During the session shares stayed in the range from $3.31 to $3.22.'
p8
aS'Sell-side Chiming in on Celldex Therapeutics, Inc.  Shares The Herald - 13 hours ago The 5 analysts offering target price estimates on shares of Celldex Therapeutics, Inc.  have set a consensus target of $6.6 on shares.'
p9
aS'Celldex Therapeutics Inc.  Soars 9.12% on March 29 Equities.com - Mar 29, 2017 Celldex Therapeutics Inc.  had a good day on the market for Wednesday March 29 as shares jumped 9.12% to close at $3.71.Celldex Therapeutics, Inc. closed with a change of -2.96% in the Previous ... - Free ObserverTaking a Look at the Data Behind Celldex Therapeutics, Inc.  - StockNewsJournal'
p10
a.